Loading
A phase 3 trial of Acalabrutinib, Prednisone, Rituximab in diffuse large b-cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) is a phase 3 interventional study registered as NCT04529772 by Acerta Pharma BV, with 611 participants enrolled, started 2020-10-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/